Jasper completes Phase 2 IgAN cohort enrollment
Jasper Therapeutics has completed the enrollment of the first IgAN cohort of its Phase 2 study evaluating vensobafusp alfa. The company anticipates reporting initial interim data by year-end 2026 and plans to accelerate an expansion cohort in FSGS patients in early 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed